Get the Stockscreener App
30.28
0.53%
-0.16
After Hours:
31.71
1.43
+4.72%
Castle Biosciences Inc Stock (CSTL) Latest News
Braidwell LP Has $9.47 Million Stake in Castle Biosciences, Inc. (NASDAQ:CSTL) - MarketBeat
43,894 Shares in Castle Biosciences, Inc. (NASDAQ:CSTL) Bought by Dynamic Technology Lab Private Ltd - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Grows Stock Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) - MarketBeat
Gene Panel Market to Surpass USD 11.75 Billion by 2031 | SkyQuest Technology - GlobeNewswire Inc.
Castle Biosciences to Present at the Piper Sandler 36th Annual Healthcare Conference - BioSpace
Castle Biosciences to Present at Piper Sandler Healthcare Conference in December | CSTL Stock News - StockTitan
Castle Biosciences (CSTL) Upgraded to Strong Buy: Here's Why - MSN
Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fourth Consecutive Year - Business Wire
Castle Biosciences (NASDAQ:CSTL) Shares Down 7.3% Following Insider Selling - MarketBeat
Castle Biosciences CEO Derek Maetzold sells $175,087 in stock - Investing.com
GSA Capital Partners LLP Takes $1.48 Million Position in Castle Biosciences, Inc. (NASDAQ:CSTL) - MarketBeat
WASATCH ADVISORS LP's Strategic Reduction in Castle Biosciences Inc Holdings - GuruFocus.com
Castle Biosciences' (NASDAQ:CSTL) Performance Is Even Better Than Its Earnings Suggest - Yahoo Finance
Castle Biosciences, Inc. (NASDAQ:CSTL) Shares Bought by Lisanti Capital Growth LLC - MarketBeat
Principal Financial Group Inc. Purchases 40,377 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) - MarketBeat
Lake Street Capital Increases Castle Biosciences (NASDAQ:CSTL) Price Target to $40.00 - Defense World
Castle Biosciences (CSTL) Is a Great Choice for 'Trend' Investors, Here's Why - MSN
Castle Biosciences' chief commercial officer sells $124,708 in stock - Investing.com India
Castle Biosciences to Present New Data Highlighting the Clinical Performance of DecisionDx®-Melanoma and MyPath® Melanoma at the American Society of Dermatopathology 61st Annual Meeting - BioSpace
Castle Biosciences' chief commercial officer sells $124,708 in stock By Investing.com - Investing.com Canada
Castle Biosciences, Inc. (NASDAQ:CSTL) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Kornitzer Capital Management Inc. KS Sells 135,636 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) - MarketBeat
Castle Biosciences Surpasses 25,000 Test Reports Delivered for its TissueCypher® Barrett’s Esophagus Test - The Bakersfield Californian
Castle Biosciences CEO Derek Maetzold sells shares worth $166,819 By Investing.com - Investing.com UK
Use of Castle Biosciences’ DecisionDx®-Melanoma Test Significantly Reduces Unnecessary SLNB Procedures, Latest Findings from Prospective, Multicenter DECIDE Study Presented at Dermato-Onco2024 - BioSpace
Castle Biosciences price target raised to $39 from $37 at Baird - Yahoo Finance
Castle Biosciences Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Castle Biosciences price target raised to $36 from $28 at KeyBanc - Yahoo Finance
Castle Biosciences director Daniel Bradbury sells $273,251 in stock - Investing.com
Castle Biosciences' chief commercial officer sells $109,709 in stock - Investing.com
Castle Biosciences director Daniel Bradbury sells $273,251 in stock By Investing.com - Investing.com UK
Castle Biosciences Inc (CSTL) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Positive Earnings - GuruFocus.com
BTIG lifts Castle Biosciences target to $45 on strong Q3 growth - Investing.com Canada
KeyBanc lifts Castle Biosciences target to $36 on test growth By Investing.com - Investing.com Canada
Castle Biosciences Inc (CSTL) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
Castle Biosciences Inc (CSTL) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance Australia
Castle Biosciences (NASDAQ:CSTL) Issues Quarterly Earnings Results, Beats Expectations By $0.14 EPS - MarketBeat
Castle Biosciences' revenue growth leads Canaccord to reaffirm $42 stock PT - Investing.com UK
Castle Biosciences (NASDAQ:CSTL) Reaches New 52-Week High After Earnings Beat - MarketBeat
Castle Biosciences (NASDAQ:CSTL) Price Target Raised to $39.00 - MarketBeat
Castle Biosciences stock target raised, outperform on strong Q3 By Investing.com - Investing.com UK
Castle Biosciences, Inc. (NASDAQ:CSTL) Q3 2024 Earnings Call Transcript - Insider Monkey
Castle Biosciences, Inc. (CSTL) Tops Q3 Earnings and Revenue Estimates - MSN
Earnings call: Castle Biosciences reports robust Q3 growth, raises guidance - Investing.com India
Earnings call: Castle Biosciences reports robust Q3 growth, raises guidance By Investing.com - Investing.com Canada
Castle Biosciences Reports Strong Q3 2024 Growth - TipRanks
Castle Biosciences Inc (CSTL) Reports Q3 2024 Earnings: Revenue Hits $85.8 Million, Net Income at $2.3 Million - GuruFocus.com
Castle Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Castle Biosciences Reports Third Quarter 2024 Results - StockTitan
Harbor Capital Advisors Inc. Acquires 15,200 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) - MarketBeat
Castle Biosciences, Inc. (CSTL) Hit a 52 Week High, Can the Run Continue? - MSN
Castle Biosciences Inc (CSTL) Q3 2024 Earnings Report Preview: W - GuruFocus.com
Castle Biosciences (NASDAQ:CSTL) Trading Down 3.8%Here's Why - MarketBeat
0.41%
0.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):